MedTrace Logo

Treatment of Knee Osteoarthritis With PAAG-OA

NCT04045431 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2024-01-08

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind clinical investigation to compare the effectiveness of intra-articular polyacrylamide hydrogel (PAAG-OA) and a hyaluronic acid, Synvisc-One to induce symptomatic benefit in subjects with knee osteoarthritis.

Conditions

  • Osteoarthritis, Knee

Interventions

DEVICE

PAAG-OA

Intra-articular injection of 6ml PAAG-OA in the target knee (incl. five (5) years follow-up) period.

DEVICE

Synvisc-One

Intra-articular injection of 6ml Synvisc-One in the target knee

Sponsors & Collaborators

  • Contura

    lead INDUSTRY

Principal Investigators

  • Henning Bliddal, MD · The Parker Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2020-10-01
Completion
2026-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04045431 on ClinicalTrials.gov